Online inquiry

IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3758MR)

This product GTTS-WQ3758MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CEACAM6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002483.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4680
UniProt ID P40199
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3758MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12315MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ11765MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-1308
GTTS-WQ6894MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA E-6011
GTTS-WQ4359MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ14215MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ7017MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ14736MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ15220MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA TACI-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW